Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sell - SGN at $2.05 Stop Limit Good Until Canceled All or None
Filled at $2.05 - 10/08/07 11:28 AM
In Reply To 'GONEOM' on 'Signalife, Inc.'
Wireless is the future! Just a matter of time!
hi techkim,
got into this stock...this stock went into gold rush last month and is looking very good...GLTY..
Daily
Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
Monday October 1, 10:03 am ET
LOS ANGELES, Oct. 1 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that is has completed in-house testing and technological evaluation of various new modules for its holter and intra- cardiac monitors - items that have previously been an important part of the Company's business plans and are now ready for submission to FDA for clearance. Applications for FDA approval will now be made imminently in the fourth quarter.
Both of these developments are ahead of schedule, and are of importance because they are both revenue producing as well as scientifically significant to the reduction of the $400 billion in cardiovascular expenses as well as to patient health and welfare. Having them completed ahead of schedule will likely bring these products to the forefront several quarters earlier than anticipated - both from a revenue standpoint as well as a scientific venturing standpoint.
NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
Wednesday September 26, 9:15 am ET
LOS ANGELES, Sep. 26 /PRNewswire-FirstCall/ -- NFL Hall of Fame, legendary wide receiver, Fred Biletnikoff, has joined the ever-growing team of celebrated athletes and entertainers as a part of the cardiovascular protection team of Signalife, Inc. (Amex: SGN - News) and Athletes for Life ("AFL"), using Signalife's Fidelity 100 and its related products and technologies. He has joined such superstars as Joe Theisman, Marshall Faulk, Tim Brown, Rocket Ismail, Jerry Rice, Dwight Clark, and Leonard Marshall in putting down their collective feet to put a stop to the late-stage, inaccurate-diagnosis-laden (diagnoses which is sometimes too little too late) assessment of heart and cardiovascular diseases.
The MVP of Super Bowl XI, Mr. Biletnikoff demonstrated on a world stage what passion and focus mean as he delivered an unprecedented performance in leading his team to an overwhelming victory in the Super Bowl.
In 1999, Mr. Biletnikoff was ranked number 94 on The Sporting News "list of the 100 Greatest Football Players." The Fred Biletnikoff Award, awarded annually to the best wide receiver in college football since 1994, was named in his honor.
Dr. Harmison, former Principal Deputy of the U.S. Department of Health Services, commented: "Mr. Biletnikoff -- one of my personal heroes -- has made the choice to make a difference in a disease-state that burdens practically every family in America and costs the U.S. Health Care industry about $400 billion per year in treating cardiovascular disease. Having someone of his stature -- a true NFL legend -- and of his demographic, will assist Signalife and AFL in addressing all of the different possible disease states and treatment options in a wider array of circumstances. I very much appreciate Mr. Biletnikoff's decision to join our cause to level the playing field for everyone."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
It has defintely found the corrct marketing mix. This company needed a Doctor. Now the doctor is applying some medicine. Expect alot more to come. It has just started.
I thought about selling this morning and taking some profit but not a chance in hell....This might be one of the best plays out there right now.
Signalife Receives Another $3.3 Million Sales Orders
Tuesday September 25, 9:15 am ET
LOS ANGELES, Sept. 25 /PRNewswire-FirstCall/ -- Earlier today, Signalife announced that it has received additional orders for the sale of $3.3 million (three million three hundred thousand dollars) of Fidelity 100 units as a continued result of new management's initial sales campaign. In the words of Signalife's President, Dr. Harmison, "That is $5.28 million of sales orders of our Fidelity 100 since I took over operational control of the Company, and -- as we fulfill our existing orders -- the Company will continue its efforts and expects to add additional sales to the system shortly."
About Signalife:
Signalife, Inc. is an award-winning life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities an Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Join iHub and ADVFN at the Traders Expo in Vegas, Nov 15 - 18, 2007!
Signalife Achieves $1.98 Million Sales Orders Thus Far
Thursday September 20, 9:03 am ET
LOS ANGELES, Sept. 20 /PRNewswire-FirstCall/ -- Signalife announced today that it has received orders for the sale of nearly $2,000,000 (two million dollars) of Fidelity 100 units thus far in its initial sales push being led by new management. Signalife, which anticipates additional sales orders resulting from its current efforts, shall announce such sales as and when they are completed.
http://biz.yahoo.com/prnews/070920/nyth045.html?.v=101
Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Monday September 10, 9:30 am ET
http://biz.yahoo.com/prnews/070910/nym078.html?.v=88
LOS ANGELES, Sept. 10 /PRNewswire-FirstCall/ -- Flanked by prominent Board members Robert Windom, M.D. and Steven Phillips, M.D., Signalife's Dr. Lowell Harmison - in conjunction with inventor Dr. Budimir Drakulic - have this day initiated the product launch of the revolutionary, one-of-a-kind, FDA- approved, ambulatory 12-lead ECG cardiovascular monitor.
In private meetings throughout the United States over the next ten days, the trio of cardiovascular experts and Signalife's award-winning technology team will present the technologies to the marquee hospitals, facilities and physician-groups that Dr. Harmison has referred to since his recent appointment as acting CEO and President. Dr. Harmison has indicated that he anticipates the product launch to generate significant movement of both devices and technologies nationwide.
Dr. Harmison commented: "I am gratified that our Board has chosen to be personally involved in my initial product launch of the miraculous Fidelity 100 heart monitor. Additionally, it is extremely important and powerful to initiate our product launch with the actual inventor - and multiple Crump Award prize winner - Dr. Budimir Drakulic, whose inventions are legendary . . . from the Air Force EEG studies to winning the Frost & Sullivan Award after completing the initial Signalife device . . ., personally present at all of the institutions and locales."
"We will be visiting more than a dozen hospitals with thousands of beds and hundreds of physicians, beginning now, in cities nationwide. These are persons we know whose reputations and business successes precede them. I am personally excited about what I call our 'insider product launch' and I am thankful to Signalife's shareholders, Board members and staff for supporting the Company through the transition and thus making this possible. I will report back to the marketplace after this launch is completed.
"For more information on Dr. Harmison's initial product launch, whether from prospective purchasers of the technologies or from investors, Dr. Harmison has asked that the Company be contacted directly or through its investor relations personnel - particularly Mr. Kevin Kading.
About Signalife:
Signalife, Inc. is an award-winning life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities an Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Legendary Earvin 'Magic' Johnson Joins AFL/Signalife Cardiovascular Protection Team
Thursday September 6, 8:51 am ET
LOS ANGELES, Sep. 6 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that the legendary Earvin "Magic" Johnson has joined Athletes for Life ("AFL") to endorse ambulatory heart testing with AFL's flagship choice, Signalife's Fidelity 100 and its related products and technologies. One of the greatest basketball superstars of all time, Mr. Johnson has also had unparalleled business successes after winning multiple championships from college to the Los Angeles Lakers to the Olympic Gold Medal. "Magic" has joined the likes of Jim Brown, Reggie Bush, Joe Theisman, Willie Gault, Thomas "Hitman" Hearns and countless other current and former professional athletes in fighting cardiovascular disease -- the number one killer in the United States. They wish to fight it by prevention -- not by watching their teammates and friends die. This is a staple of AFL and Signalife.
Signalife, Inc. President Dr. Lowell Harmison -- an AFL member, a former collegiate running back, and former Principal Deputy of the United States DHHS -- commented that "I am personally overjoyed that Earvin "Magic" Johnson -- as he is historically famous for -- has shown the field of vision to understand that something is wrong when we have millions of people being deprived of the ability to obtain a complete 12-lead ECG signal of their own heart when they are moving (ambulatory). The heart is a muscle. To be unable to properly test that muscle when it is "at work" is -- we believe -- the cause of significant failures in detection of disease. This is an undisputed fact."
"To have somebody with Mr. Johnson's background and achievement become a part of this cause is very gratifying to me, to all of the 50+ founding members of Athletes for Life and to the Board controlling the only device capable of capturing the data, seeing the signals and leveling the playing field -- Signalife's Fidelity 100," added Dr. Harmison.
Willie Gault, the co-founder of Athletes for Life, stated that "As we continue to expand the reach of sponsorship in favor of the utilization of Signalife's technologies to all portions of our society, the cost of cardiovascular disease -- to the government, to society and to individuals of all income levels -- will change dramatically. To have my friend "Magic" Johnson as a part of the team is something I personally appreciate and is a development that will significantly support and assist our efforts on assuring that this is an endeavor that reaches all portions of our society. This is a very exciting day for me."
Two years ago, Mr. Gault experienced the horror of having three close friends -- former NFL superstars -- die of sudden heart attack at very young ages and while having clean bills of health from their physicians. The proliferation of the Fidelity 100 -- Signalife's FDA approved heart device -- is intended to change the status quo where these tragic events repeatedly occur and where there is no resulting change in cardiovascular care. In the words of Mr. Gault: "The change is upon us now, and AFL will be there to assure it has the appropriate reach into all socio-economic portions of society."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Signalife to Deploy Fidelity 100 Heart Monitors for AFL
Tuesday September 4, 10:40 am ET
LOS ANGELES, Sept. 4 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has committed to deploy Fidelity 100 Heart Monitors in more than 12 urban centers to screen for testing of sudden cardiac death and cardiovascular disease, events that will be financed by Athletes for Life, A Non Profit Foundation ("AFL"), through mobile centers though which AFL will bring health care to each community. AFL includes as its founders and members some of the world's greatest living and legendary athletes including, for example, current NFL star Reggie Bush, John Elway, Jim Brown, Marshall Falk, Olympic Gold Medal Winner Maurice Green, Jackie Joyner-Kersee, Gayle Sayers, Lee Elder, Anthony Munoz and Olympic Gold Medal Winner Willie Gault.
The events will be centered around screening and testing patients of all ages in everyday ambulatory environments, when the heart is at work. No other device can measure the full disease spectrum with the accuracy of the fidelity 100 when the subject is moving or when noise (artifact) is present. In the words of Signalife President and Chief Executive, Lowell T. Harmison, "It is impossible to level the playing field without giving everybody an opportunity to identify the signals about their health at the earliest possible opportunity. We are very thankful for AFL's insistence on assuring that the medical community eradicate the current cardiovascular crisis in America where $400 billion is spent annually with paltry preventative results for our middle and lower classes and the majority of society."
Under the arrangement, physicians will be present when AFL conducts its screening programs in various communities. AFL anticipates that it will conduct many of these programs using its prototypical moving "medical center truck". AFL has indicated that additional health care testing and screening will be provided in these centers. This screening program is a continuation of AFL's wellness program initially tested and developed at health clubs.
"The Company will provide a video on its website of the events, which will be covered by the print, internet and television media so that the entire world can see with its own eyes the importance of accurate signal detection," added AFL Founder, World-Class sprinter, Gold Medal Winner, and Super Bowl winner, Willie Gault.
AFL plans to have several additional members join as founders in preparation for these events, and Signalife will announce these superstars as they are signed. In California, track and screening locations have already been identified in Orange, Los Angeles, San Bernardino and San Francisco Counties and the public will be invited to meet the celebrity athletes -- and other celebrities -- within two weeks of each event.
AFL exclusively uses Signalife's Fidelity 100 for coronary testing, because the Signalife device is the only one able to detect the presence of coronary artery disease in an ambulatory environment, and for other reasons. Signalife is providing dozens of devices for the first series of events, at reduced price points for the AFL 501 (c)(3) charity.
For more information, please contact Signalife's corporate offices; however, the company will issue additional press releases as each event approaches.
Signalife Provides Corporate Update
Friday August 31, 8:34 am ET
Friday, August 31, 9:15 am ET
LOS ANGELES, Aug. 31 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News), Lowell T. Harmison, President and acting Chief Executive, has release the following corporate update since his matriculation into the Presidency last month:
1. Dr. Harmison has already "cleaned house" and has eliminated several
positions that were producing no revenue whatsoever and no hope of any
positive results for the Company, in his view. That was done
immediately by Dr. Harmison and was done by the Dr. personally. "We
are now operating within five separate departments: Sales, R&D,
Operations, FDA, Regulatory. These positions are now compartmentalized
and operating efficiently under my direct supervision."
2. As promised, and as announced, Dr. Harmison has participated in
obtaining a $102 million financing vehicle for the Company. Dr.
Harmison calls this an "extremely valuable" facility, because it
enables the company to choose the market conditions - and stock price -
at which it shall exchange its stock for capital." Dr. Harmison
continues: "We are thankful to the AMEX for so efficiently and in good
faith evaluating and approving our financing transaction. The market
appears to be getting the message that - when my sales initiatives bear
fruit in the upcoming near term - the obtaining of $100 million at the
market price is a testament to our technology - referred to as a
"modern medical miracle" by NBC. Any other result would have been
unfair to our shareholders, and I promised that I would create a new
era for our shareholders - one with revenues, earnings, profits, growth
and corporate accolades."
3. According to Dr. Harmison, "our sales funnel utilizing marquee
hospitals known to the Company and its Board" is proceeding ahead of
schedule. These are some of the prestigious institutions in the
country and allow the marvelous Fidelity 100 to be utilized in areas
where lives and outcomes can be changed for the better. I anticipate
our market penetration strategy over the next five quarters will
proceed more quickly than I had conservatively anticipated at the
beginning of my tenure."
4. The technology division is also moving on its holter devices as well as
its intra-cardiac monitor - and other devices - with extraordinary
acuity and speed. The division - possibly the core of the Company -
"only gets more efficient as the secrets of the patented technologies
become more known and understood in the quality of the signal from
heart patients of all ages."
"In short, I have achieved more than I anticipated in several short weeks, and the momentum toward device approvals, ventures, sales and earnings are at the center of that gaining momentum. I am still planning on a near-term conference call with the marketplace, but I wish to complete certain touchstone events before having that call. I am always available for shareholder calls and can be reached through our corporate offices," added Dr. Harmison.
About Signalife:
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Good Luck on the stock! The [product should be sweeping the nation and along with the global medical communities. Monitor services are the forfront against heart disease and diagnosis.
What is holding it back is the acceptance of initial added costs, like most new products on the market. It is exremely effective in comparison to present day monitors.
Liked the chart, just bought in today~ go SGN! :)
Signalife Completes $102 Million Financing
Monday August 20, 9:15 am ET
LOS ANGELES, Aug. 20 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has just released to the news wires that it has received American Stock Exchange Approval for up to $102 million in financing with Yorkville Advisors, LLC through its YA Global Investments LP fund.
As part of the financing, Signalife has received immediate funding of $2 million through the sale of its common stock to YA Global Investments, and has also entered into a Standby Equity Distribution Agreement (SEDA) allowing Signalife, at its sole discretion upon effectiveness of a registration statement relating to the shares underlying the SEDA, to sale up to $100 million in additional common stock to YA Global Investments over the next three years. The company shall now proceed forward with its newly constituted Board and immediate sales initiative. The market should expect a status conference call from President and former FDA-head Lowell Harmison later this month or immediately after Labor Day.
When Dr. Harmison took the post, he promised immediate financing and he has delivered.
Commenting, Dr. Harmison said: "What a professional group of financiers we met with at Yorkville Advisors' San Diego office. Every ounce of their diligence centered around our revolutionary technology and the concomitant business evaluation. They were on point, serious and they completely 'get it' in all respects. We look forward to a successful tenure with them as we enter our commercialization phase and over the long term."
About Signalife:
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
SGN financials 8/10/07
10QSB 1 signalife10qfor63020078fored.htm 08/10/2007
http://www.sec.gov:80/Archives/edgar/data/810365/000081036507000011/signalife10qfor63020078fored.htm
Heisman Trophy Winner Reggie Bush Joins Signalife Cardiovascular Protection Team
Thursday August 9, 9:36 am ET
LOS ANGELES, Aug. 9 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced former Heisman Trophy Winner, and NFL superstar, Mr. Reggie Bush has joined Athletes for Life ("AFL") to endorse ambulatory heart testing with AFL's flagship choice, Signalife's Fidelity 100 and its related products and technologies. One of the greatest college running backs of all time, Mr. Bush now plays in the National Football League and wishes to join the likes of Joe Theisman, Willie Gault, Anthony Munoz, Jim Brown and countless other current and former professional athletes in fighting cardiovascular disease - the number one killer in the United States. They wish to fight it by prevention - not by watching their teammates die. This is a staple of AFL and Signalife.
Signalife, Inc. President Dr. Lowell Harmison - an AFL member, a former collegiate running back, and former Principal Deputy of the United States DHS - commented that "It is impressive that a young man with Mr. Bush's talents has had the keen insight to understand what his predecessors have learned: Cardiovascular disease kills and it kills in seconds. As the former head of the FDA, I can tell you that Mr. Reggie Bush understands the game and all the games more than you all know. That is, he understands football (obviously) and he understands the game of life. For he knows that one of life's greatest gifts is good health. It all begins with heart health. His joining AFL (and Signalife) and sharing in their mission and work is a gigantic step toward helping to save lives from heart attack and leveling the playing field across the underprivileged communities and across the United States in general. I applaud and thank him for his generous and well thought out support. Along with such celebrities as John Elway, Jim Brown, Rick Barry, Vida Blue, Dwight Clark, Clyde Drexler, Marshall Falk, Jim Hill, Rocket Ismail, Deacon Jones, Andre Reid, Willie Gault, Gale Sayers, and Fred Williamson, I will assure that this playing field is leveled for all times and all seasons. It is already happening and I will assure its continued success. This is a serious matter and these celebrity athletes (and more) have given their names and good will to assure that we at AFL do our job - and we shall do just that. The miraculous Signalife technologies are being manufactured and matriculated not only in the United States but across the world and they will give precious data in ambulatory environments where the heart muscle shows its true forms and where the truth reveals itself."
Willie Gault, the founder of Athletes for Life, stated that "As the current and active professional superstar - like Reggie Bush - pushes the utilization of Signalife's technologies to all portions of our society, the mortality rate and outcome for all members of our society will improve dramatically. That is my dream, and I thank Reggie for helping me."
Athletes for Life, A Non-Profit Corporation, now boasts an unparalleled following for the Signalife technologies including such current and former superstars in a list unparalleled in any other philanthropic agency. No AFL member is compensated for his or her endorsement. In the words of Mr. Gault - who holds the world record time for the 100 meters after the age of 40 (and still competes with men of all ages) - "It is all about saving lives, and my friends understand this."
Heart Response Under Extreme Conditions - Signalife Technology Featured on CBC
Friday July 27, 9:24 am ET
GREENVILLE, S.C., July 27 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that a video footage of its technology use during Champ Car Grand Prix of Edmonton is now available online. The report was made by Terry Reith of Canadian Broadcasting Company (CBC) during last weekend's race in Edmonton. To view the video, please click on Signalife link below:
http://www.signalife.com/Pages/newsPDF/2007/pr07252007.html
Signalife patented signal processing technology enables recording of high- fidelity ECG data in harsh environment. The collaboration between the Signalife and Champ Car started in the Fall of 2005, as a joint three-way collaborative effort, when Dr. Jennifer Cummings of Cleveland Clinic introduced Signalife R&D team to the Champ Car World Series (CCWS) Medical Director Dr. Chris Pinderski. Open cockpit race cars, such as in CCWS, house a large number of electronic instrumentation and communication devices and also subject drivers to constant vibrations of the road course and high G-force impacts. This harsh environment represents a great challenge for ECG monitoring. In addition, due to discomfort, drivers could not tolerate the use of traditional wet-gel electrodes for recording ECG data. As a result, dry electrodes and a custom designed garment have been developed. The use of dry electrodes on unprepared skin represented enormous challenge for quality ECG recordings. During a race, driver is fitted with a special fire-protective shirt with embedded dry electrodes and ECG signal is recorded by the on-board recorder while heart rate information is transmitted over vehicle telemetry channel. After two years of development, Signalife system performed flawlessly during two races in Canada.
Dr. Budimir S. Drakulic, Signalife Chief Technology Officer stated: "The first phase of our joint effort with Champ Car World Series and Jennifer Cummings, MD of Cleveland Clinic is successfully accomplished. We can collect and transmit in real time ECG data during a race. Physicians from Champ Car and Cleveland Clinic will be able to analyze and use these data to enhance performance and safety of drivers."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Signalife Adds Three Prominent Board Members
Monday July 16, 9:15 am ET
LOS ANGELES, July 16 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced early today that it has added three very prominent physicians -- two of which are former senior officials in governmental health departments, and all of which are successful businessmen -- to its Board of Directors. With these additions, the Company intends to form a Technology Review and Distribution Committee of its Board, to guide the current initiatives involving the Company.
Added to the Board are Steven Joseph Phillips, M.D., Robert E. Windom, M.D. and Jay A. Johnson, M.D. All three physicians have extensive business, regulatory and practical experience in cardiology and health care. The physicians also have extensive experience in one or more different but complementary medical areas that will use the Signalife Fidelity 100 heart monitor for slightly different purposes and benefits -- cardiology, internal medicine, and cardiac surgery -- which will allow the company to use their expertise to develop strategies to more effectively market the Fidelity 100 in each such area. In addition to acting as directors and assisting the company in developing its product placement marketing strategies, the physicians will also introduce the company and the Fidelity 100 to numerous "marquee" hospitals and physician groups.
Steven Joseph Phillips, M.D.
Dr. Phillips, from Bethesda, Maryland, is currently engaged by the National Institutes of Health. He served as a cardiac surgeon at Iowa Heart Center from 1974 to his official retirement date of 2005 -- a span of some 30 years. Dr. Phillips' achievements and experience are literally too broad in scope to list in a press release. They will be outlined in more detail on the Company's website. Among these are his positions at the prestigious Cardiac Hospitals of America, a for profit organization with which Dr. Phillips is still involved. Prior to that, Dr. Phillips was Deputy to the Director of Research and Education, National Library of Medicine, National Institutes of Health. Some of his other more recent positions include the National Science Advisor for the Iowa Department of Health as well as serving on the Board of Directors in Iowa for the American College of Cardiology. Dr. Phillips received his Bachelor of Arts from Hobart College, Geneva, NY and his Doctor of Medicine in 1966 from Tufts University School of Medicine, Boston, MA. Afterwards, Dr. Phillips served with the United States Army in the 101st Airborne Division, 27th Surgical Hospital. Over the years, Dr. Phillips has published hundreds of scientific articles in medical journals.
Commenting on his appointment to Signalife's Board, and after a thorough technology review, Dr. Phillips said: "The spectrum of technology presented by Signalife exceeds by magnitudes all existing systems. The Fidelity 100 is the 'grail' of ambulatory EKG monitoring that I have been seeking for nearly 40 years. In my opinion, the Signalife Fidelity 100 and associated technologies will create a paradigm shift in the way we monitor and detect cardiac life threatening events. The Fidelity 100 will save lives and is appropriate not only for cardiac patients, but for the general public as well."
Robert E. Windom, M.D.
Much like Dr. Phillips, Robert E. Windom, M.D. possesses an array of experience and industry-wide connections that are critical at this juncture of Signalife's development. A graduate of Duke University -- both undergraduate as well as his medical degree -- Dr. Windom has had an extremely distinguished career in internal medicine and cardiology through his practice in Sarasota, Florida. Among other appointments, Dr. Windom is currently the President of the World Immuno Society for Health, a member of the Board of the Florida Medical Directors Association, a Special Advisor to the Secretary, Florida Department of Health, and numerous other public and private Boards spanning a spectrum of health care to banking. Dr. Windom has also received numerous awards throughout his distinguished career, including Distinguished Internist of the Year from the American Society of Internal Medicine. Over his career, Dr. Windom has engaged in significant international activities as an Assistant Secretary of Health, and is the author of over 30 publications.
In evaluating the prospects for the technology, Dr. Windom said he was "amazed" that a cardiac device "can receive such a precise recording under many and varied conditions." Dr. Windom "foresees" that the Fidelity 100 "will revolutionize the industry because there is nothing on the horizon that approaches its accuracy." In the words of Dr. Windom, the result is "better patient care."
Jay A. Johnson, M.D.
Dr. Johnson is a Board Certified Internist and Cardiologist. Currently, Dr. Johnson is an attending physician at Stanford University Hospital. He holds a Bachelors degree as well as both a Masters Degree and a Medical Degree, the latter from George Washington University in 1990. He is the recipient of numerous awards, including from the American College of Cardiology.
Commenting on his appointment to the Company's Board, Dr. Johnson -- who has been working with and evaluating the technology for nearly one year -- called the technology "remarkable." Continuing, he indicated that "the Signalife, Fidelity 100 is the most advanced technology in ECG monitoring available today. The ability of the Fidelity 100 to capture clean ECG tracings in an active, ambulatory setting will greatly enhance our ability to detect cardiac disease early and will lead to life-saving intervention."
SGN -- Signalife, Inc.
Com ($0.001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
BUYINS.NET: Signalife, Inc. (SGN) SqueezeTrigger Price is $2.04.
Approximately 8.7 million Shares Shorted Since August 2005 According to
Buyins.net Research Report
Jul 11, 2007 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, is
reiterating coverage of Signalife, Inc. (AMEX: SGN) after releasing the
latest short sale data to July 2007. From August 2005 to July 2007
approximately 60 million total aggregate shares of SGN have traded for a
total dollar value of nearly $122.5 million. The total aggregate number of
shares shorted in this time period is approximately 8.7 million shares.
The SGN SqueezeTrigger price of $2.04 is the volume weighted average short
price of all short selling in SGN. The next of several short squeezes is
expected to begin when shares of SGN close above $0.83, where
approximately 288,000 shares have been shorted. To access SqueezeTrigger
Prices ahead of potential short squeezes beginning, visit
http://www.buyins.net.
Month Total Vol. Short Vol Avg.Price $Value
Aug 05 1,190,300 248,590 $3.22 $800,460
Sept 1,847,000 385,739 $3.45 $1,330,800
Oct 507,300 105,948 $3.18 $336,915
Nov 540,300 96,200 $3.01 $289,918
Dec 1,011,300 293,952 $2.57 $754,163
Jan 06 1,142,500 159,230 $3.08 $490,190
Feb 821,300 142,565 $3.10 $441,780
Mar 820,000 215,300 $3.08 $662,155
Apr 1,046,900 211,020 $3.10 $654,078
May 645,200 148,796 $2.59 $385,322
June 1,675,900 298,250 $2.41 $717,947
July 1,244,400 268,200 $2.92 $783,841
Aug 1,164,200 230,600 $2.42 $557,752
Sept 1,446,400 153,667 $2.04 $313,112
Oct 1,346,200 312,600 $1.76 $548,894
Nov 2,253,200 439,925 $1.69 $741,802
Dec 4,645,700 363,700 $1.25 $456,189
Jan 07 9,466,900 1,260,834 $1.70 $2,137,240
Feb 7,823,310 848,901 $1.96 $1,662,742
Mar 4,653,380 695,619 $1.89 $1,318,128
Apr 4,629,200 692,004 $1.66 $1,146,789
May 4,978,400 661,840 $1.31 $868,069
June 3,743,400 288,242 $0.83 $239,241
July 1,345,200 166,523 $0.63 $104,910
Tot 59,987,890 8,688,245 $2.04 $17,742,437
*short volume is exact through May '07 and approximated thereafter using a
proprietary algorithm.
**average short price is calculated using a volume weighted average short
price.
***short volume is the total short trade volume and does not account for
covers.
About Signalife, Inc.
Signalife, Inc. is a life sciences company focused on the monitoring and
detection of disease through continuous biomedical signal monitoring.
Signalife uses its patented signal technology to design and develop
medical devices that simplify and reduce the costs of diagnostic testing
and patient monitoring in an ambulatory setting. Signalife is publicly
traded on the American Stock Exchange under the symbol SGN. The website
for the company is http://www.Signalife.com. Clear Data. Trusted Results.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of
publicly traded US companies fight naked short selling. Naked short
selling is the illegal act of short selling a stock when no affirmative
determination has been made to locate shares of the stock to hypothecate
in connection with the short sale. Buyins.net has built a proprietary
database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to
generate detailed and useful information to combat the naked short selling
problem. For the first time, actual trade by trade data is available to
the public that shows the attempted size, actual size, price and average
value of short sales in stocks that have been shorted and naked shorted.
This information is valuable in determining the precise point at which
short sellers go out-of-the-money and start losing on their short and
naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and
publishes a proprietary SqueezeTrigger for each stock that has been
shorted. The SqueezeTrigger database of nearly 1,450,000,000 short sale
transactions goes back to January 1, 2005 and calculates the exact price
at which the Total Short Interest is short in each stock. This data was
never before available prior to January 1, 2005 because the Self
Regulatory Organizations (primary exchanges) guarded it aggressively.
After the SEC passed Regulation SHO, exchanges were forced to allow data
processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over
7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly
8,000 OTCBB and PINKSHEET stocks. Each month the database grows by
approximately 50,000,000 short sale transactions and provides investors
with the knowledge necessary to time when to buy and sell stocks with
outstanding short positions. By tracking the size and price of each
month's short transactions, BUYINS.NET provides institutions, traders,
analysts, journalists and individual investors the exact price point where
short sellers start losing money and a short squeeze can begin.
All material herein was prepared by BUYINS.NET, based upon information
believed to be reliable. The information contained herein is not
guaranteed by BUYINS.NET to be accurate, and should not be considered to
be all-inclusive. The companies that are discussed in this opinion have
not approved the statements made in this opinion. Signalife, Inc. has
purchased one year of monthly reports from BUYINS.NET at the cost of $995
per report. The data service can be cancelled at any time. This opinion
contains forward-looking statements that involve risks and uncertainties.
This material is for informational purposes only and should not be
construed as an offer or solicitation of an offer to buy or sell
securities. BUYINS.NET is not a licensed broker, broker dealer, market
maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities viewed
on or mentioned herein. BUYINS.NET will not advise as to when it decides
to sell and does not and will not offer any opinion as to when others
should sell; each investor must make that decision based on his or her
judgment of the market.
BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market
professionals. As a member, visitor, or user of any kind, you accept full
responsibilities for your investment and trading actions. The contents of
BUYINS.NET, including but not limited to all implied or expressed views,
opinions, teachings, data, graphs, opinions, or otherwise are not
predictions, warranty, or endorsements of any kind. Please seek stock
market advice from the proper securities professional, or investment
advisor.
By visiting BUYINS.NET or using any data or services, you agree to assume
full responsibility for the decisions or actions that you undertake.
BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates,
advertisers, information providers and any other associated person or
entity, shall under no circumstances be held liable to the user and/or any
third party for loss or damages of any kind, including but not limited to
trading losses, lost trading opportunity, direct, indirect, consequential,
special, incidental, or punitive damages. As a user, you agree that any
damages collected shall not exceed the amount paid to BUYINS.NET and/or
its owners. As a website user, you agree that any and all legal matters of
any kind are to be reviewed and handled in their entirety within the State
of California only. By using the services of this website, you are
consenting to the terms as outlined, and forfeit all legal jurisdictions
in any other State.
Past performance is not a guarantee of future outcomes. Any and all
examples are hypothetical and should not be considered a guarantee or
endorsement of such trading activity. BUYINS.NET does not take
responsibility for problems of any kind, including but not limited to
issues with operations, data accuracy or completeness, contacting issues,
technical issues, and timeliness. BUYINS.NET places great integrity on the
data collected and distributed. This information is deemed reliable, but
not guaranteed. All information and data is provided "as is" without
warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or
services from a securities professional. You should consider these factors
in evaluating the forward-looking statements included herein, and not
place undue reliance on such statements. The forward-looking statements in
this release are made as of the date hereof and BUYINS.NET undertakes no
obligation to update such statements.
This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are
generally preceded by words such as "may", "future", "plan" or "planned",
"will" or "should", "expected," "anticipates", "draft", "eventually" or
"projected". You are cautioned that such statements are subject to a
multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those
projected in the forward-looking statements, including the risks that
actual results may differ materially from those projected in the
forward-looking statements as a result of various factors, and other risks
identified in a companies' annual report on Form 10-K or 10-KSB and other
filings made by such company with the SEC.
CONTACT: Thomas Ronk, CEO, www.BUYINS.net Tel: +1 800 715 9999 e-mail:
Tom@buyins.net
M2 Communications Ltd disclaims all liability for information provided
within M2 PressWIRE. Data supplied by named party/parties. Further
information on M2 PressWIRE can be obtained at http://www.presswire.net on
the world wide web. Inquiries to info@m2.com.
(C)1994-2007 M2 COMMUNICATIONS LTD
**********************************************************************
As of Saturday, 07-07-2007 23:59, the latest Comtex SmarTrend? Alert, an
automated pattern recognition system, indicated a DOWNTREND on 04-26-2007
for SGN @ $1.49.
For more information on SmarTrend, contact your market data provider or go
to www.mysmartrend.com
SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright
? 2004-2007 Comtex News Network, Inc. All rights reserved.
New Patent Awarded to Signalife
Tuesday July 10, 9:15 am ET
LOS ANGELES, July 10 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that The United States Patent and Trademark Office has awarded the Company a new and important patent, which the Company has now added to its significant intellectual property portfolio.
The patent, which covers 56 claims, was awarded on all such claims by the Patent Office. Patent attorney and Signalife's Board member Ellsworth Roston supervised and prosecuted the patent application along with Chief Technology Officer Budimir S. Drakulic - the Company's inventor. The new patent is owned by Signalife, Inc.
In conjunction with the Patent Office's granting of the patent - entitled "Electrode For, and Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body" - the Company will now evaluate whether or not it will file a continuation or continuation-in-part application for the purpose of pursuing additional claim coverage in the technology that may have occurred since the time of the original application.
Budimir Drakulic called the patent-issuance-development a "major milestone in the continued proliferation and protection of the Company's core technologies and products." Dr. Drakulic said he was gratified at the "many years of enormous expertise and energy that Mr. Roston has expended in the prosecution of all patents as well in the development of the Company's sophisticated intellectual property position."
The medical device maker currently has an application for its "credit card" size, over the counter (non-prescription), device pending before the Food and Drug Administration as well as several additional patents pending before the United States Patent and Trademark Office covering a wide array of cardiac technologies and products. Dr. Drakulic stated that he is "confident the Company will continue to be successful in obtaining approval of its technologies and products in these endeavors."
Signalife Recorder Transmits Heart Rate Data From Champ Car Driver in Real- Time
Friday July 6, 3:58 pm ET
GREENVILLE, S.C., July 6 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that it has successfully developed and tested a novel ECG recorder capable of real-time transmission of Champ Car driver heart rate data from the vehicle to the team's computers. The system was first tested June 22-24, 2007, during the Grand Prix of Cleveland and will be tested again during the Grand Prix of Toronto to be held July 6-8, 2007 in Toronto, Canada.
In addition to real-time heart rate transmission, the Signalife device is capable of broadcasting single ECG channel data via vehicle telemetry system. Simultaneously with transmission, the novel ECG recorder can store three full clinical-bandwidth ECG channels in the internal recorder memory for later review by the physicians.
Continuous ECG recording with live transmission capability has never been previously done on open-cockpit race car drivers. As a leader in motorsport safety, the Champ Car World Series (www.champcar.ws) and its Medical Director Dr. Chris Pinderski along with Cleveland Clinic physician Dr. Jennifer Cummings wanted to monitor driver ECGs for possible heart rhythm abnormalities in high G-force impacts which may alter on-site treatment by safety and medical personnel. Dr. Pinderski stated: "We are always looking at ways to make racing safer for our drivers. This technology allows us to monitor our drivers more closely and helps us to improve our onsite treatment. Signalife has been a great partner throughout this process and we are very happy to continue to work with them."
The acquisition of electrocardiographic (ECG) data in the harsh environment of an open cockpit race car presents several challenges. To address these challenges, Signalife developed a novel ECG recorder capable of acquiring full clinical-bandwidth data from drivers participating in the Champ Car racing. "The data that we have been able to collect during development of this monitor is of high quality, especially considering harsh environment in which it is recorded," stated Dr. Cummings. "The monitor performed well at our first live heart rate telemetry test and I am excited to see how it develops even further this season." In addition to safety, the Champ Car drivers benefit from the recorded ECG data as they can better tailor physical training and improve their fitness level for the race.
Dr. Budimir Drakulic, Signalife CTO, stated: "We are grateful to Dr. Cummings from Cleveland Clinic for introducing us to this challenging problem. Dr. Pinderski and Dr. Cummings provided us with continuous medical guidelines during the device development. We are extremely satisfied with the performance of our technology in this challenging environment. Monitoring driver's ECG during a race from medical trailer is now a reality."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Signalife Adds Dr. Harmison As President And Chief Operating Officer, and Announces Intent to Raise Capital To Comply with AMEX Continued Listing Requirement
Tuesday July 3, 5:20 pm ET
GREENVILLE, S.C., July 3 /PRNewswire-FirstCall/ -- Interimly, Signalife, Inc. (Amex: SGN - News) has appointed Dr. Lowell Harmison as its President and Chief Operating Officer. Signalife is the company that has created and produces the new state-of-the art Fidelity 100 Heart Monitor. Dr. Harmison, who has been a director of Signalife since 2002 and a principal advisor in the development of its product-set, has a distinguished 40-year career in the field of biomedicine, including serving as the Principal Deputy Assistant Secretary for U.S. Public Health Service, Department of Health and Human Services under the Reagan Administration. In that capacity, Dr. Harmison was a Chief Operating Officer in charge of managing a budget of $14 billion and more than 40,000 employees.
Most recently, Dr. Harmison was a founder and served as a director and the first chairman of the Sequella Global TB Foundation, now the AERAS Foundation, Aeras is a multimillion dollar non-profit organization working through public- private partnerships to develop new TB vaccines and ensure that they are distributed to all who need them around the world, and served as a director and as Chairman of the board of World Doc Foundation, a private foundation promoting health education and expanded knowledge of telemedicine, since June 2002. Prior to that time, Dr. Harmison served as the Chief Operating Executive of the multi-billion-dollar Maxwell Foundation.
Dr. Harmison is the holder of the first domestic and foreign patents on the fully implantable artificial heart. He has written and completed a comprehensive book on the heart, which is now in publication.
Over the last several months, Signalife has been in discussions with a number of large prospective industry partners relative to joint venturing and other arrangements pursuant to which they would adapt Signalife's technology and products for a variety of applications, and Signalife would utilize their sales and marketing channels to penetrate the market. Due to Signalife's limited management and resources, it has not been in a position to expeditiously pursue these opportunities or to otherwise rapidly bring its products to market. Dr. Harmison's principal responsibility will be to take the lead role in effectively marketing the company's Fidelity 100 heart monitor and other products, including introducing the Fidelity 100 to marquee hospitals and leading cardiologists, and to otherwise develop the company's marketing plans and managing its sales and marketing. Dr. Harmison will also assist in negotiations with certain prospective joint venture and other partners, and oversee certain operational activities, including product development and manufacturing.
In furtherance of his appointment, which has been approved by the full Board of the Company, Dr. Harmison stated: "I have decided to spend the necessary time and energy in bringing Signalife's Fidelity 100 - and later its other products - to the marketplace because I believe that there is no technology in the world that can duplicate what Signalife's technology can do for both preventative and primary cardiovascular care."
On June 27, 2007, Signalife received a deficiency letter from the American Stock Exchange ("AMEX") pursuant to which it indicated that the company 's current stockholder's equity of approximately $3.2 million had fallen to less than the $4 million and $6 million required for continued listing under AMEX Rules 1003(a)(ii) and (a)(iii), respectively. These minimum stockholders' equity thresholds were triggered by the recent decline of Signalife's market capitalization to less than $50 million, which previously exempted Signalife from these requirements. Pursuant to the letter, Signalife will be required to submit to AMEX by July 27, 2007 for its review and acceptance of a plan for so increasing the company's stockholder's equity, which plan will need to be implemented by December 29, 2008 or such earlier date as AMEX deems reasonable. If the company's market capitalization were to return to levels above $50 million, then the plan will not need to be implemented. Signalife is presently preparing a plan to submit to AMEX to address these matters. No guarantee can be given that AMEX will accept the plan, which would lead to a delisting of Signalife's common shares from AMEX.
Although Signalife will have approximately 18 months or such shorter period of time as deemed reasonable by AMEX to increase its stockholders' equity pursuant to the company's proposed plan, the company will nevertheless take immediate steps to substantially increase its' stockholders' equity to well over the $6 million threshold.
As noted above, AMEX's deficiency letter was triggered by the recent decline of the company's market capitalization to less than $50 million. As previously disclosed by Signalife in a news release dated May 16, 2007, BUYINS.NET reported that over 8.2 million common shares were shorted from June 2005 to May 2007 in connection with the sale of approximately 53.4 million shares. Based on updated information, Signalife believes that an additional 1 million common shares were short-sold since the press release was issued. Signalife believes that these shorting activities have had an adverse effect on share price. Based upon data provided by BUYINS.NET at its website, Signalife further believes that a portion of these short sells were uncovered (i.e., naked) or otherwise illegal under the federal securities laws. In view of these concerns, Signalife has previously requested that AMEX's Market Surveillance Department -- which has the responsibility for monitoring and policing the market under AMEX Rule 702 -- to conduct an appropriate investigation and take appropriate action.
According to Dr. Harmison, "Signalife is extremely concerned with the effect of unlawful short selling on Signalife's stock price and resultant ability to raise capital. The company intends to aggressively pursue its options to investigate and remediate this problem, both privately and regulatorily. The recent revelations as discussed above concerning this young company are threatening patient lives as well as the monetary ability of the United States to deliver effective health care to tens of millions of its citizens. I am not going to allow these unlawful initiatives to get in the way of changing the paradigm of cardiovascular care. Nevertheless, based upon my discussions with investors and my knowledge of the medical industry, I am confident that significant additional capital will be flowing into the company through product sales and capital sources, irrespective of stock price or regulatory action or inaction of the manipulative short selling that has occurred. The technology is simply too important and too timely to, in my view and based upon my discussions, yield any result other than that my efforts on behalf of the company will be successful."
About Signalife, Inc.
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife, Inc. is the recipient of the Frost & Sullivan Technological Innovation Award for 2006.
Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at www.signalife.com.
Caution Regarding Forward-Looking Statements
In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. For example, no assurance can be given that the AMEX will approve Signalife's proposed plan, or that Signalife's common stock will continue to trade on AMEX. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
FDA Certifies Signalife Fidelity 100 ECG Monitor System for Export to Mexico
Monday July 2, 9:15 am ET
GREENVILLE, S.C., July 2 /PRNewswire-FirstCall/ -- Signalife, Inc. ("Company"), (Amex: SGN - News) announced today that it has received a Certificate to Foreign Government which allows the importation of the Signalife Fidelity 100 ECG Monitor System into Mexico certifying that a firm and its devices are in compliance with U.S. law. The certification states that the Fidelity 100 may be marketed in, and legally exported from the United States to Mexico as the manufacturing plant is considered to be in substantial compliance with current Good Manufacturing Practices, the product is properly registered and listed, 510(k) cleared and meets all labeling requirements.
"This is an important milestone for the company as there has been interest in markets outside the US for a product that offers both clinical advantages for the healthcare community, but also has applications in the wellness industry. Now we are poised to sell units in this market that has waited patiently for this approval," states Bill Matthews, Signalife's Director of Regulatory Affairs.
About Signalife, Inc.
Signalife, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient's cardiovascular system. Signalife is based in Greenville, South Carolina. For more information visit http://www.signalife.com.
Signalife Hires Director of Sales
Thursday June 28, 9:15 am ET
GREENVILLE, S.C., June 28 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) -- Signalife, Inc. announced that it has hired Elizabeth Peacock as its Global Director of Sales. Ms. Peacock has a broad knowledge of the healthcare space with a focus on cardiovascular medical devices. Throughout her career she has gained experience in sales and marketing leadership as well as business strategy. She speaks four foreign languages (French, Italian, German, and Spanish) which allow her to take advantage of opportunities in international markets as we gain the required approvals to sell in those countries.
She received her BA degree in England from Bath University in business and languages where she graduated Magna Cum Laude. In addition she earned an MA from Reading University where she again graduated with honors, Magna Cum Laude.
Upon graduation, she began her career with Johnson and Johnson's Ortho Division in The Middle East and Africa. She then came to the US and was employed by Intermedics, Inc. with implantable cardiovascular products and infusion pumps.
She joined Research Medical and acted as Director of Sales for seven years and was able to drive sales increases of over 20% year over year culminating in Research Medical's acquisition by Baxter. Ms. Peacock was actively involved in the acquisition negotiations and transition strategies. She was retained by Baxter's Intercontinental Division and received a promotion to head up business strategies for the cardiovascular products group. She also participated in the preparation to spin off Baxter's CardioVascular Group to form Edwards Lifesciences.
Since leaving Baxter, Ms. Peacock has been involved with two start up companies, firstly as Vice President of Sales and Marketing for Hancock Jaffe Laboratories, a developer of cardiovascular and vascular tissue grafts, and most recently as Vice President of Sales & Marketing for Ameritox, a specialty diagnostics company.
"We are excited to welcome Liz to our team as we focus efforts on revenue generation. She has a tremendous history of success creating sales results and we look forward to her success driving revenues for Signalife, stated Pam Bunes, CEO of Signalife, Inc.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance for heart monitoring and other biomedical devices incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical devices incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Signalife, Inc., Receives Industry Canada Certification
Tuesday June 26, 9:08 am ET
GREENVILLE, S.C., June 26 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced today that it has received Industry Canada (IC) certification which allows the importation of the Signalife Fidelity 100 ECG Monitor System for marketing and sale into Canada. The certification states that the device is in compliance with the necessary requirements for medical devices of this type. Therefore, the Fidelity 100 may be marketed in, and legally imported from the United States into Canada.
Revenues for ECG devices in the Canadian market exceeded $200 million in 2006. Canada's health care system is a group of socialized health insurance plans that provides coverage to all Canadian citizens. It is publicly funded and administered on a provincial or territorial basis, within guidelines set by the federal government.
Under the Canadian health care system, individual citizens are provided preventative care and medical treatments from primary care physicians as well as access to hospitals, dental surgery and additional medical services. With a few exceptions, all citizens qualify for health coverage regardless of medical history, personal income, or standard of living.
Canada does boast one of the highest life expectancies (about 80 years) and lowest infant morality rates of industrialized countries, which many attribute to Canada's health care system.
"Approval to sell our product in Canada is another significant milestone for the company as the country's focus on preventative healthcare will be addressed by the signal quality of the Fidelity 100 and its ability to detect minimal cardiac problems at an early stage of the disease progression, thus arming physicians with better diagnostic data. The access to more accurate data may allow physicians to utilize various treatment options for patients before cardiovascular disease progresses to its most debilitating stages," states Pam Bunes, CEO of Signalife, Inc.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance for heart monitoring and other biomedical devices incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical devices incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
SIGNALIFE, INC. Annual Meeting
Meeting Date: 06/23/2007 for holders as of 05/31/2007
CUSIP: 82669P-104 Your Control Number: 574835732725
If you plan to attend the meeting Click here.
Meeting Materials
10K REPORT
Proxy Statement
As your vote is very important, we recommend that all voting instructions be received at least one business day prior to the voting cut-off time stated in the information circular. Scroll down for proxy instructions and voting.
Scroll down for proxy instructions and voting.
Proxy Ballot:
Directors' Recommendations:
Choose this if you would like to vote your shares following directors' recommendations.
See below or refer to the proxy statement for the detailed recommendations. Please read them carefully.
Vote
01. DIRECTOR(S):
Directors Recommend a vote FOR election of the following nominee(s):
(1) PAMELA M. BUNES (2) ELLSWORTH ROSTON (3) LOWELL T. HARMISON
(4) JENNIFER BLACK (5) ROWLAND PERKINS (6) CHARLES H. HARRISON
(7) JESSE S. ROSAS
For all nominees Withhold all nominees For all EXCEPT those selected below
PAMELA M. BUNES
ELLSWORTH ROSTON
LOWELL T. HARMISON
JENNIFER BLACK
ROWLAND PERKINS
CHARLES H. HARRISON
JESSE S. ROSAS
02 . RATIFICATION OF THE APPOINTMENT OF ELLIOTT DAVIS, LLC, AS SIGNALIFE'S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2007.
Directors Recommend: FOR
For Against Abstain
03 . ALL OTHER MATTERS THAT MAY PROPERLY BE BROUGHT BEFORE THE ANNUAL MEETING FOR VOTE BY THE HOLDERS OF THE COMMON AND SERIES 'A' PREFERRED SHARES, OR ANY POSTPONEMENTS OR ADJOURNMENTS THEREOF, AS TO WHICH THE UNDERSIGNED HEREBY CONFERS DISCRETIONARY AUTHORITY UPON SAID PROXIES.
Directors Recommend: FOR
For Against Abstain
What’s the Flavor of the Month? Medical Devices.
By MATT RICHTEL
Published: June 11, 2007
http://www.nytimes.com/2007/06/11/business/businessspecial3/11venture.html?_r=1&ref=businessspec...
LUKE EVNIN contends there is money to be made giving people with fading vision a poke in the eye.
Mr. Evnin is a venture capitalist at MPM Capital, which in December contributed to a $41 million financing round for NeoVista, a Silicon Valley company with a novel idea for treating the wet form of macular degeneration, an eye disease that can lead to blindness. The idea is to stick tiny probes into the eye to irradiate the retina and stem the growth of blood vessels that cause the condition.
Such an investment is emblematic of a trend among venture capitalists to pour money into medical-device companies, at the expense of past favorites like computer-related start-ups or drug-development companies.
In the first quarter of this year, seed investors put $1.1 billion into such businesses, a quarterly record for the medical-device industry, and a 60 percent increase over the same period in 2006, according to the National Venture Capital Association, a trade group.
These investments in recent years have financed a range of technologies, including devices designed to unclog arteries, rebuild heart valves, monitor body functions from within, limit chronic pain and spinal problems and treat sleep dysfunction, acid reflux, epilepsy and diabetes.
“The venture-capital-backed boom in medical devices has delivered extraordinary new technologies,” said David Cassak, an editor at In Vivo, a monthly publication for the medical-device field. “There’s virtually no sector of medical devices that hasn’t been given a tremendous boost.”
Medical investments are by nature high risk, and devices take time and millions of dollars to develop. They must also be tested for safety and usefulness and then receive regulatory approval. It is a business that generates sales of $15 billion to $20 billion a year, and the venture capitalists are betting on its expanding into new niches.
Part of the lure, analysts and executives said, is that medical devices feel like a smarter gamble than investing in computer technology, which has fallen out of favor with public-market investors. Interest by these investors is critical for venture capitalists who want to profit by selling shares of their start-ups on Nasdaq.
At the same time, venture capitalists and entrepreneurs who are attracted to life sciences are wary of investing in pharmaceuticals, which can typically take 10 years and cost several hundred million dollars to come to market. Devices typically can be developed in half the time and for much less.
Meanwhile, demand for new health care solutions continues to rise, particularly among the baby-boom population, which generally has deep pockets and is fascinated with technological advances.
“We are all used to the idea that our BMW tells us when our tire is flat,” said Paul S. Kedrosky, executive director of the William J. von Liebig Center for Entrepreneurism and Technology Advancement at the University of California, San Diego. “The idea of a device telling us that our blood glucose is low is pretty appealing to people.” A device’s function, he added, is also easier for venture capitalists to grasp than, say, the workings of a new drug, which can require a background in chemistry and biology to understand.
“Devices are much easier to understand for a repurposed venture guy,” like someone who used to be immersed in the computer industry, Mr. Kedrosky said.
Still, the devices can be complex. The NeuroVista Corporation (formerly BioNeuronics), a Seattle business that recently received $34 million in venture money, has engineered a gadget that can be implanted in the cranium to monitor brain signals and recognize a possible onset of an epileptic seizure; it then delivers its own signals to try to prevent the attack.
EndoGastric Solutions, another company in the Seattle area, has developed a surgical device designed to cure acid reflux. It is inserted through the mouth to repair a faulty esophageal valve by stapling a piece of stomach to it.
The innovations are making surgical procedures less invasive and risky, thus creating alternatives to drug therapy, said Mr. Evnin of MPM Capital, which focuses on life sciences and is based in San Francisco. It has also invested in EndoGastric Solutions.
The new developments “reduce the chasm between a surgical procedure and taking a pill,” Mr. Evnin said. “There’s been pretty creative thinking about what used to be pharmaceutical markets, and now we’re bringing engineering solutions.”
But Mr. Evnin and other investors say the development periods are long, and new devices often require testing on patients and approval from the Food and Drug Administration. For instance, NeoVista, the start-up that says it has a treatment for macular degeneration, has good safety data and is in clinical trials, but is still two to three years from the market, Mr. Evnin said.
“The investment and time required, while substantial with devices and frankly longer than it used to be, is still modest compared to what you need for drugs,” he said.
Another challenge is that when problems arise with products, they can take a major toll. For instance, the publicized concerns that drug-coated arterial stents can cause blood clots created an uproar last year among doctors, patients and investors.
There is also a general concern that these markets are cyclical. Medical-device investing was also strong in the mid-1990s, but crashed later in the decade as public-market investors turned to information technology. The current record investment in devices has spurred some to say that the market might be overfinancing technologies.
“It could create overheated sectors and put too much money to work,” said Mr. Cassak of In Vivo magazine, though he added that the influx of investments into medical-device research was a big net positive so far. “It’s hard to see the current interest as anything but good news.”
Signalife Begins Penetration of Foreign Markets
Wednesday May 30, 10:03 am ET
GREENVILLE, S.C., May 30 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced that physicians outside the United States are excited to have access to the company's proprietary signal processing technology in the Fidelity 100 ECG System and have ordered the product for use in both practices and clinics.
During a recent patient evaluation, a physician using the Fidelity 100 on a patient indicated that she believed the patient had a variety of heart complications, but prior to use of the Fidelity 100, she had been unable to identify the condition adequately. She immediately ordered the Fidelity 100 for her practice and indicated that many patients in Mexico would benefit from its availability.
"It is exciting to witness the physician delight with Signalife's technology and to realize how it will impact their patients' lives. In the US, we have a great variety of diagnostic tools for physicians use, but in Mexico, the ECG is considered a valuable diagnostic tool that is well utilized by physicians. Even the subtleties of the device and its signal processing capabilities are highly valued and recognized," stated Pam Bunes, CEO of Signalife, Inc. "We anticipate great success in Mexico and the rest of Latin America as we continue our sales effort in those markets."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance for heart monitoring and other biomedical devices incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical devices incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Email Story
Set News Alert
Print Story
yes, it looks very promising. I've been watching SGN for months now and finally decided to jump in today. This isn't a quick flip, a swing trade at best I like the potential in the technology
Share price does not reflect what this wireless invention will do for mankind in the future. The future holds great things for this wireless invention.
I do know there are some deals in the works, but they to do take time. The quote below hints at some sort of business deal(s).
Tuesday May 8, 9:15 am ET (yahoo/SGN)
'We made initial steps during and following the ACC Meeting and are hopeful to finalize certain business opportunities at Heart Rhythm 2007" stated Pamela Bunes, CEO, of Signalife, Inc."
http://biz.yahoo.com/prnews/070508/nytu013.html?.v=86
SGN being deliberately shorted. It is so obvious! The company has been in contact with AMEX over the situation. Something is going to go down and its not SGN per say.
Signalife to Exhibit at Heart Rhythm Society Meeting 2007
Tuesday May 8, 9:15 am ET
GREENVILLE, S.C., May 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that it will exhibit at the Heart Rhythm Society 28th Annual Scientific Sessions to be held May 9 - 12, 2007 at the Colorado Convention Center in Denver, Colorado. It is expected that the Heart Rhythm Meeting in 2007 will attract over 8,000 Heart Rhythm management professionals and 5,500 Heart Rhythm society members. The exhibit will provide unique exposure for Signalife to demonstrate its award wining technology and products.
To demonstrate the superiority of the Signalife technology, world-class athlete and Super Bowl winner Willie Gault of the 1985 Super Bowl Champions Chicago Bears will wear the Fidelity 100 and 300 devices while running on a treadmill at high speeds. The devices will garner clinical-quality ECG signals that will be displayed on a wide screen monitor for easy viewing. The demonstration will take place at the company's booth #373 on both Thursday and Friday at 11am and 2pm.
"We are pleased to be exhibiting at Heart Rhythm 2007. The ACC 2007 presentation in March was extremely successful and our industry colleagues are aware of our capabilities to generate a high-fidelity ECG signal in a harsh environment. We are going to pursue different business opportunities for the best possible application of our technology. Our ultimate goal is to identify strategic partners, in addition to our already sizeable distribution channels, that can assist in the distribution of our technology for numerous applications. We made initial steps during and following the ACC Meeting and are hopeful to finalize certain business opportunities at Heart Rhythm 2007" stated Pamela Bunes, CEO, of Signalife, Inc.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
This has to be about SGN! It is an unsolicitated offer by some company I never heard about. The company does not know of these people either. highly interesting!
SIGNALIFE INC. (AMEX:SGN)
Only company they be talking about have to be SGN
------------------------------------------------------
http://www.web-purchases.com:80/DIM/EDIMH424/landing.html?sessionID=PcL1XjuFK&o=1235672&u=16....
Do You Have What It Takes?
By the way -- my name is A.M. Sosnowski. I'm a senior investment analyst for Taipan Financial News Group, a financial news and research network, based out of Baltimore, Maryland since 1987.
As the editor of both WaveStrength Trader and Diligent Investor (and a frequent contributor to the Taipan newsletter), I spend my days analyzing stock charts and pinpointing lucrative trading opportunities for roughly 23,000 readers.
I don't mean to brag, but in 2006 alone, my readers racked up gains of 150%, 58%, 75%, 65%, 54%, 53%, 50%, 25%, 40%, 37%, 29%, 32%, 31%, 26%, 29% and many more.
Not too shabby. Especially when you consider our conservative low-risk approach. But here's the thing: About once a month, I uncover a tiny stock that makes the above gains look like child's play.
A stock just like the one NBC refused to name back on November 30, but that I'm ready to give you here today.
I research and report on these stocks in my new service, Diligent Investor's MicroCap HotSheet.
Now, this micro cap is already red hot. Its stock price has actually posted gains of over 100% since the beginning of 2007!
This is only the beginning for this company's wild ride of big returns.
But the thing is -- not everyone who reads this letter will be able to be on board.
Because due to the small size of this company, and the volatility of micro-cap stocks such as this one, I've got to set down a few guidelines before I release this information to you.
The Today Show was unable to release the name of this company due to its insanely large viewing audience. It was just too dangerous -- both to the network's reputation as well as the company's.
The integrity of its work, and the value of its stock had to be protected. That's why NBC was forced to leave viewers empty-handed when it came time to name the stock symbol for this "Modern Medical Miracle" maker.
So with that in mind, before we go on, I need to check to see if you qualify to receive this confidential information that could be worth 1,042%.
Qualification No. 1: You must be comfortable with micro caps. The stocks I recommend are small. In some cases, they may be very volatile.
And while the stocks have the potential to soar tenfold, they can also experience rapid price declines. An opportunity such as this one is only for people who are comfortable putting a small amount of money into a potentially huge winner.
Qualification No. 2: You must be able to keep a secret. No blabbermouths. Sharing this information with people who are not within our private group is strictly prohibited.
Why?
Because it puts our profit opportunities at risk! One of the reasons we allow so few Members is so everyone can get in BEFORE the stock takes off.
If we have hoards of extra people riding our coattails... it could prevent some of our Members from grabbing maximum profits.
Bottom line: Keep the picks confidential for 48 hours. You can share war stories with your friends and family AFTER we take gains. Fair enough?
Qualification No. 3: You must act now. As I mentioned earlier, FDA approval for this company's groundbreaking cardiac technology could be handed down as soon as next month.
I'd hate to see you miss out on the incredible run of gains that I'm confident will occur once that approval is granted.
Remember, I'm predicting that this $1.75 company could go as high as $20 a share. That's a 1,042% gain for investors who are on board for the entire joyride.
If you hesitate even for a few days, it may already be too late.
So now if you meet all three of these qualifications -- let's not waste any more time.
I want to be the first to tell you all about this company's incredible medical breakthrough, and why I'm almost certain you could be among the select few sitting on at least a 1,042% gain by 2009.
The $1.75 Company Taking on
America's No. 1 Health Epidemic
In 2003 heart disease killed more U.S. women than cancer, lung disease, diabetes, and Alzheimer's... combined.
One out of every 2.7 deaths in the United States is caused by it and the estimated cost of treating heart disease is $403.1 billion per year, up 41% since 1999.
Even more shocking is that 40% of all U.S. hospital revenues are generated by cardiovascular disease. And it doesn't appear to be slowing down, unless something is done about it.
Even though costs of treating this dreadful disease have risen substantially, experts agree that 85% of cardiovascular disease can be prevented or even halted by early diagnosis.
There are more than 100 million resting electrocardiograms (or ECG's) performed annually, but doctors agree that monitoring the heart during everyday activity is the best bet for diagnosing conditions early.
Enter this $1.75 micro cap with the technology to do just that.
Even the tight-lipped Today Show hailed it as a "Modern Medical Miracle" and it's not exaggerating.
This company has developed a painless, easy way for people to monitor their heart rate every day, without sitting in a doctor's office, or wearing an uncomfortable bulky device.
This technology has the potential to save millions of lives, as it serves as an incredibly accurate early warning for heart disease.
And once FDA approval is handed down in the next few months, this tiny company is likely to explode up to 1,042%, as it tries to keep up with the demand for its proprietary technology.
Two Products in Line for Approval...
Big Gains Sure to Follow
This company already has one of the most powerful ECG monitors on the market for early prevention of heart disease. But it's not stopping there.
Just recently, this micro-cap announced the introduction of two new products that will revolutionize the way we detect cardiovascular disease... and the amounts of money we spend treating it...
The company just completed a dry holter that needs no skin prep to be worn. It can't be detected under clothing. Most importantly, it's lightweight, thin and comfortable. A simple memory chip embedded in the vest can tell doctors in minutes what's irregular about a patient's heartbeat.
This "cardio-vest" is the technology The Today Show did its story on recently, calling it a "Modern Medical Miracle," but not revealing the penny-stock company behind it.
You see, this vest is enabling doctors to monitor a patient's heart rate accurately and easily. All you need to do is slip the vest on, and you're instantly broadcasting your heart- beat back to a monitor.
Doctors aren't the only ones using it either.
During the Today Show story it was revealed that race-car drivers on the wildly popular Champ Car circuit are now wearing the vests while they drive, so that their teams can ensure that the driver's heart rate is maintaining a safe and steady level throughout the race.
The potential for this cardio-vest doesn't end in the doctor's office or the driver's seat of a race car though.
Sports teams, fitness centers, research laboratories, medical schools, athletic trainers... all of them use heart monitors on a regular basis, and this tiny company's technology is only going to make it even easier for them to continue.
When Angeion, one of the medical penny stock goldmines I mentioned earlier, began marketing Medgraphic, its proprietary cardio and respiratory diagnostic system, to sports and fitness centers, its share price soared from $1.78 all the way up to $17.61.
In the short term, based on the FDA approval and release of this cardio-vest technology, I believe this company will hit at least $10 and could go as high as $20 after that, handing you a 1,042% in the process.
But the vest isn't the only product this $1.75 micro cap is gearing up to release.
The company also has a personal heart monitor that can be purchased over the counter. It's so small it fits in your wallet, and can be used at any point to check your heartbeat. You set it on your chest and you're off to the races... figuratively, of course.
This device is the size of a credit card and uses the company's patented technology to monitor a person's heart, any time, anywhere.
All you need to do is pull it out of your wallet, hold the small device over the center of your chest, and instantly your heart rate is sent electronically to a physician or monitoring center.
Instant info for your doctor to make sure that your heart is doing exactly what it should be!
The company just finished testing and completed design and manufacturing specifications in the last month.
The personal heart monitor is now headed for regulatory approval. And once it's handed down, that will serve as yet another catalyst for this $1.75 company to blast off even higher in value.
Just these two products alone can take the $400 billion Americans use to treat cardiovascular disease, and use it instead to prevent it.
Profits are going to come quick for this company: FDA approval for its technology is pending and should be fast.
That's because one of the experts on its Board of Advisors is actually on the FDA Medical Devices Advisory Committee.
That's right, this company actually has one of its own people on the inside of the industry's ruling body!
You better believe it knows what the company needs to do to secure approval, and how to do it fast at that. This means the time to get in on this company is right now, so you can be on board for that full 1,042% gain I'm predicting.
Even MORE Big News Coming
From This Hot Penny Stock
Just to add even more fuel to this company's fire, it's recently announced even more big news.
First came word that it had reached an agreement with Gold's Gym, the ultra-popular nationwide fitness center chain, to begin in-house cardiac testing with its equipment at Gold's original and largest location in Venice Beach, CA.
Testing is available to all gym members when they come in to work out, and if it proves to be successful, you can be sure that Gold's will be quick to start installing this company's cardiac monitors in its hundreds of locations across the country.
That'll mean a very sizeable order could be delivered to this $1.75 company very soon.
It would be wise to own a piece of it before it does.
The company has also recently unveiled a prototype device used to test the effectiveness of existing ECG machines that physicians and trainers are using right now.
This is going to prove to be a brilliant move on its part, because once this device is tested on current equipment, all it will serve to do is show doctors that these devices are clearly inferior to the heart monitoring technology this tiny company is preparing to release.
And you can't argue with results like these when you see them clear in front of your face, just as this device is expected to do.
This company's existing products are already making ripples as well.
Its first official heart-monitoring product has been sold and shipped to surgeons, cardiologists, and even a multibillion-dollar corporation.
After more than 50 surgeries using the device, doctors have stated that the product has "...benefits too numerous to mention."
And best of all, this is all patented technology. This micro-cap company is "aware of no other system that can acquire a similar ECG signal in any ambulatory environment with the use of metal electrodes compatible with [its] cardiac vest."
This company has flown under the radar for far too long.
Because of its size and small market cap, situations like the one occurring with NBC have been necessary to protect the value of the company and the integrity of its products.
But soon, those days will be over. This company could very well be on the front pages of every major financial publication and talk show in the country.
It's just lining up piece after piece of cutting-edge heart technology. Once its approvals are granted, and these devices hit the market, this company is poised to become one of the major players in the medical equipment industry.
It's essentially holding a loaded gun, just waiting for the go-ahead to start firing.
And when it does, its share price is going to start moving up by leaps and bounds.
I really believe the sky's the limit with this micro cap.
I love the potential of the company's cardio-vest alone, which has to send its share price through the roof.
And that's not to mention the other technology it's developing, and the partnerships it's forming in other industries. Those are just icing on the cake!
And while I'm extremely bullish on the company's prospects, there's only one problem.
Only a handful of the folks who read this letter will be allowed to profit from the information I'm about to reveal.
In fact, most people will be intentionally excluded so that a smaller private group can enjoy the full rewards.
The good news is, if you met the three qualifications outlined earlier, you'll most likely grab yourself a huge piece of the action as this tiny medical device company revolutionizes the way we view and treat cardiovascular disease.
Make no mistake: What you're about to discover could hand you a potential 1,042% gain, at the least, in the next two years.
Still think 1,042% is an outrageous prediction?
Well, just take a look at the track record of some companies almost identical to this one, over the past few years...
A History of Shocking Gains...
Tiny medical technology companies, just like the one I've discovered today have been shocking Wall Street with explosive triple- and quadruple-digit gains and sending many an investor into an easy and early retirement for years now
Sure, they're not flashy or heavily hyped. You don't hear their names thrown around on TV a lot.
But that's actually a good thing for you.
Because with its stock prices trading for only a few measly dollars per share, there's little risk and yet unbelievable reward for the few potential investors who take the time to locate them.
For instance...
Just imagine if you'd been on board for the kind of ride IMClone Systems Inc. experienced a few years ago.
In July 2002, its share price sat at $7. Decent, but nothing all that special for an investor looking to build their wealth on a grander scale.
But when its signature cancer drug Erbitux cleared FDA hurdles and hit the market soon after, IMClone absolutely exploded.
Just 24 months later, in July 2004, its price sat at $86.
A 1,128% gain for investors who got in back at the $7 price tag!
Or what if you'd owned shares of Palomar Medical Technologies, an equipment company that specializes in manufacturing lasers for medical and cosmetic procedures, back in February 2003, when it sold for just $1.30?
One month later, when it introduced its newest technology, the Medilux Pulsed Light System, its share price began a steady climb upward that never stopped.
In October 2003, it followed that up with the release of a lower priced version of the Medilux, aimed specifically at the beauty industry.
And in February 2005, it was back again, when it unveiled an infrared deep-heating device for pain relief use.
All the while, its share price kept shooting up. And by March 2005, it sat at $29.50.
A 2,169% increase in just two years.
And to top it off, today its price sits at over $40 a share! That's almost a 3,000% gain! And it's still climbing!
You could have owned it at just $1.30...
But those are just isolated examples right? Lightning in a bottle for a few lucky investors...
Wrong. Believe it or not, these kinds of massive micro-cap gains aren't uncommon at all. They happen more often than you think.
It's just a matter of being able to identify the right companies early enough, so that you're on board for the entire profits ride, not just a piece of it.
Take Onyx Pharmaceuticals for example...
Back in July 2002, this small drug company partnered with pharmaceutical giant Bayer to develop an anti-kidney cancer drug called BAY 43-9006.
Its stock price sat at an unimpressive $4.03.
But as testing began to take place on the drug, the success it had at shrinking tumors was released to the public. Onyx caught fire.
By the time BAY 43-9006 received a fast track designation towards approval by the FDA, early investors were sitting atop a mountain of profits.
Onyx's share price hit a high of $58.75 in May 2004.
A 1,357% gain in just 22 months...
Now the only way an investor could have collected every last penny of that 1,357% gain was to be in on Onyx before it began releasing its test results and creating a huge buzz on the market.
But what about when Onyx's share price began to fall a few months later?
How does an investor ensure that they know when to sell so that they're able to hang onto quadruple-digit gains?
Or when to buy in again... like investors should have a few months ago, when Onyx went back up over 100% in just one day thanks to successful trials of their new cancer drug Nexavar?
Well, what if they had an expert, someone with their hand on the pulse of the industry, teaching them exactly what to do and when to do it, to ensure they maximize their gains on stocks like these?
Imagine what kind of success you could have with a micro-cap guru like that, alerting you to the most sure-fire cheap stocks whose prices are ready to blow through the roof.
With research and analysis from an expert like that, you could be sitting on countless triple- and quadruple-digit winners in your portfolio.
Winners such as Angeion Corporation, a small Minnesota-based company that manufactures and markets medical devices and fitness products, including a non-invasive cardio diagnostic system.
Back in mid-2004, Angeion was selling for only around $1.20 a share. That's peanuts!
And as recently as January 2005, you could still purchase it for under $1.80.
But why would you? A company languishing under $2 for years... for most investors it sure didn't look like a "must-own" stock for their portfolio.
Well most investors were wrong, and in 2006 Angeion spread its wings and soared.
Its Medgraphic cardio and respiratory diagnostic system hit a sales bonanza in the health, sports and fitness industries, becoming an essential piece of equipment for doctors, trainers and coaches to use in obtaining an overall picture of an individual's cardio-respiratory health.
Just a few days before I sat down to write you this letter, I took a look at Angeion's stock price.
It had shot as high as $18.50 a share.
That's a 1,441% increase from its $1.20 price point!
What if you had gotten word about Angeion and its cardio technology back in 2005, long before customers were lining up around the block, eager to shell out millions to purchase it?
If you'd bought 1,000 shares at $1.20 in mid-2004, you'd have turned $1,200 into $18,500 in just over two years.
Try finding a return on your money like that anywhere else!
Want to Know Who the Next Big
Penny Stock Winner Will Be?
You may be starting to see a trend here...
Micro-Cap Gains Like This Happen
More Often Than You Think... So Why Aren't You Grabbing Some?
Medarex -- $3 to $97... 3247% gain!
Pacific Ethanol -- $1.62 to $42... 2987% gain!
Midway Games -- $2.10 to $12.63... 601% gain!
Essex Corp -- $1.55 to $20.87... 1346% gain!
Ixia -- $3.36 to $15.59... 464% gain!
Novatel Wireless -- 91 cents to $27... 2987% gain!
Cassella Waste Systems -- $3.88 to $14.20... 366% gain!
Netflix -- $5.22 to $77.66... 1488% gain!
Psychiatric Solutions -- $1.49 to $67.88... 4542% gain!
Packateer Inc. -- $2.66 to $23.10... 868% gain!
These incredible micro-cap success stories I've been telling you about are all centered in the health and medical equipment industries.
Their successes were all based on the introduction of a product to the market that has not only helped to improve doctors' ability to diagnose, heal and prevent medical conditions, but has actually fundamentally changed the way they're able to do it.
All of these innovations were of course subject to FDA approval also. Once that ruling is handed down, you can almost set your watch to the profit boom that will follow.
And taking all those factors into account, I believe I've discovered the next in line in these micro-cap gold mines.
At this moment, this tiny $1.75 company that NBC deemed too dangerous to reveal on air, is awaiting FDA approval on a piece of ground-breaking medical technology that could not only change the way doctors prevent heart disease, but could also send this little-known stock's value soaring over 1,000% by the end of the year.
But the question remains... how is the average investor supposed to know which of these tiny companies is in store for big things, and which is selling for chump change for good reason?
There is an easy way to find out. And to use that information to your portfolio's advantage...
And in the long run, it coul also provide you with a series of blockbuster micro-cap gains... delivered to you personally... each and every month.
A Tidal Wave of Tenbaggers
So how valuable would it be for you to have a micro-cap expert, doing all the research and handpicking the absolute best growth stock opportunities on the market today for you?
That's exactly what I'm proposing I do for you today. But I can only do it for a small group of readers.
Until recently, I've been unable to recommend these kinds of surefire micro-cap winners to my 23,000 readers of WaveStrength and Diligent Investor.
You see, these micro-cap stocks are small. But they don't stay that way for long. In fact, some of them go on to deliver astronomical returns.
Many of them, in fact, have soared tenfold. Some have even returned 20-to-1.
Bottom line: I've had to keep my mouth shut, and watch quietly as these stocks bolt into orbit.
Force Protection (FRPT.OB) Is a Perfect Example...
Force Protection is located on Highway 78 in Ladson, South Carolina. It designs and manufactures ballistic and blast-protected military vehicles -- things like tanks and patrol vehicles.
When I first discovered Force Protection back in December 2005, it was trading for about 70 cents per share. I knew right away that FRPT was destined for big gains.
Unfortunately, I couldn't recommend FRPT to my WaveStrength or Diligent Investor readers.
Why?
Because the stock was a micro cap... so small that only a small fraction of my readers would have been able to get in at the 70-cent price before the added volume pushed the stock much higher.
Think about it: 23,000 people rushing into a tiny micro-cap stock would double, triple or quadruple the price very quickly. Because I want all my readers to be able to profit from my recommendations, I had to set FRPT aside.
Let me tell you right now, it was pure agony to let Force Protection slide... because even though I couldn't recommend it, I knew it was a home run in the making.
And you know what? I was right.
In fact, in the following months, FRPT took off. The stock quickly doubled... and doubled... and doubled again!
By June 2006, FRPT hit $6 and kept on going, eventually hitting $17.20 on Dec. 6, 2006. When all was said and done, Force Protection went from 70 cents to $17.20 in less than a year.
That's a gain of over 2,345%!
People who got in early could have made 23 times their money in 12 months!
I come across a micro-cap stock like FRPT about once a month. And I wish I could tell my readers about them. Unfortunately, the very best companies are simply too small to recommend to my entire file of over 23,000 readers.
Tix Corporation (TIXC.OB) is another example...
Tix Corporation is based in Studio City, California. Right outside of Hollywood, it's big in "show biz."
In fact, its primary source of revenue is ticket sales to Las Vegas shows. Sounds kind of funny, I understand. But the thing is, these guys are making money hand over fist.
When I first spotted TIX back in May 2006, it was trading for 35 cents.
I knew right away TIX was headed for the big time. But, because it had a tiny market cap, I couldn't recommend the stock to my 23,000 readers.
You can probably guess what happened. TIXC.OB took off almost immediately.
Practically overnight, TIX doubled. By October, it had doubled again. And by December 2006, it hit $5.90 per share! Take a look at the chart:
That's a fifteen-fold return in about six months!
But as I said, I couldn't recommend TIX to my readers. Sure, some of them would have gotten in. But the majority would have missed out.
I come across a lot of stocks like Tix Corporation when I run my weekly stock screens. In fact, I uncover at least one hot micro-cap stock every month. And while not all of them go gangbusters, many of them deliver stunning triple- and quadruple-digit gains. For example:
Cambridge Heart, Inc. (CAMH.OB): This medical research firm went from 25 cents in December 2005 to $3.80 in November 2006. That's over 1,000% in 11 months.
Patriot Scientific Corporation (PTSC.OB): This microprocessor company went from 20 cents in January 2006 to $2.25 in March 2006. That's 1,000% in three months.
Foamex International (FMXI.PK): This polyurethane manufacturer went from 30 cents in April 2006 to $4.10 in August 2006. That's 1,000% in four months.
Frontier Development Group (FRG.TO): This uranium miner went from 75 cents in September 2004 to $8.23 in April 2006. That's almost 1,000% in 18 months.
Strata Oil & Gas (SOIGF.OB:OTC): This Canadian oil exploration company went from 79 cents in September 2005 to $7.95 in July 2006. That's nearly 1,000% in 10 months.
International Tower Hill Mines (ITH.V): This junior gold miner went from 34 cents in May 2006 to $3.40 in September 2006. That's 900% in four months.
Katanga Mining (KAT.TO): This copper company went from $1.14 in June 2005 to $8.45 in April 2006. That's over 640% in 10 months.
ECU Silver (ECU.V): This silver miner went from 35 cents in December 2005 to $3.65 in September 2006... just under a 1,000% gain in 9 months.
Blue Pearl Mining (BLE.TO): This exploration company went from 70 cents in January 2006 to $7.55 in October 2006... close to a 1,000% gain in under 10 months.
Of course, these stocks have already had their big run. It's too late to buy them now. But here's the good news for you:
I've just isolated the next micro-cap sensation...
This micro-cap $1.75 medical device company is set to deliver a 1,042% gain, and probably even more than that in the long run.
Could This $1.75 Stock Be a Possible Tenbagger?
Absolutely! In fact, I wouldn't be surprised if it went all the way to $20 per share in the next few years.
And here's the best part: While this tiny company is too small to recommend to my 23,000 readers... I've figured out a way to share it with you today!
This is a very exciting time for me. As you can imagine, I've been going near crazy the last couple years... watching these micro-cap stocks skyrocket... and not being able to tell anyone about them!
I'm not about to let this next stock get away.
Like I said, this next micro-cap sensation could be the biggest winner of all.
Most people don't know about this company yet. It's too small. But in the coming months, I bet we'll see big institutions and mutual funds begging to buy this stock for $4... $6... even $10 per share.
You can get in today for $1.75!
Small Private Group = Big Advantage
As the editor of WaveStrength Trader and Diligent Investor, my goal is to help people make quick conservative gains. And I've done just that. In fact, in the last year alone, my readers have pulled in gains of:
150% in 2 days...
58% in 9 days...
75% in 31 days...
65% in 31 days...
54% in 1 day...
53% in 9 days...
50% in 26 days...
25% in 1 day...
40% in 1 day...
37% in 1 day...
29% in 5 days...
32% in 4 days...
29% in 1 day...
32% in 9 days...
31% in 5 days...
30% in 6 days...
26% in 2 days...
29% in 3 days.
All in quick options gains!
But I'm a stock picker by heart.
So in addition to those option plays, my readers have made such substantial gains in short periods of time on stocks like:
115% on China Life Insurance in six months...
114% in four months on China Southern Airlines...
81% in six months on Almost Family Inc., a home health-care provider...
And even 136% in six months on MasterCard Inc.'s IPO...
Pretty good. Thing is, I realized that my readers are missing out on some of the best micro-cap opportunities. Companies such as:
Cambridge Heart, the medical research firm that soared from 25 cents to $3.80, a 1,000% gain in 11 months...
Or Patriot Scientific Corporation, the microprocessor company that bolted from 20 cents to $2.25, a 1,000% gain in 3 months...
Or Foamex International, the polyurethane manufacturer that jumped from 30 cents to $4.10, over 1,000% in 4 months...
Or Blue Pearl Mining, 64 cents to $6.97... a 1,000% gain in under 10 months...
Or ECU Silver, 35 cents to $3.65... a near 1,000% gain in 9 months.
I hate seeing stocks that I discover shoot up in price without your being able to benefit from the information.
That's why I decided to launch a new private group called Diligent Investor's MicroCap HotSheet.
Membership in MicroCap HotSheet puts you in elite company -- a truly small group of savvy individuals looking to profit from sizzling hot micro caps.
With MicroCap HotSheet, you'll receive at least one of the very best micro-cap stocks I uncover each and every month.
These stocks will be small companies most people have never heard of. And while not all of them will work out, many of these stocks could go on to deliver tenfold gains.
Just like the $1.75 medical technology stock NBC couldn't tell you about, but that I'm ready to reveal to you today.
If you sign up for MicroCap HotSheet, I'll rush you a Special Report that will give you all the information The Today Show wasn't allowed to, including the name of the company and ticker symbol.
I truly believe this stock is a surefire tenbagger and will rise at least 1,000% in a couple of years.
Of course, as a Member of MicroCap HotSheet, it will only be the first in an ongoing flow of micro-cap winners.
As I mentioned, I come across a new micro-cap stock at least once a month. And when I do, you'll be the first to know. Not all of these companies will deliver 1,000% gains. But as you can see above, the chances of pocketing big gains... are very realistic.
Unfortunately, most people are going to miss out on this opportunity.
Membership Spots Available for a Short Time Only
When I initially launched MicroCap Hotsheet I limited enrollment to only 500 Charter Members.
Needless to say, those spots filled up almost instantly.
Ever since then, I've been receiving e-mails from readers who were shut out of those 500 spots.
I guess they've been hearing the buzz about the great opportunities we've been discovering in Hot Sheet.
Now as I told you before, because these micro-cap stocks are small companies, it would be difficult for me to send this information to thousands and thousands of people.
But I've decided, because of the incredible demand for Membership, to open up MicroCap HotSheet for a limited enrollment period ONLY.
I simply can't allow too many people to take advantage of these tiny growth stocks.
If I just left our Membership open constantly for anyone to join, the surge of trading volume would drive the price through the roof before most people had a chance to get in early.
Once these limited spots fill up, I'll be forced to once again close out enrollment and watch volume levels carefully. Only after I'm satisfied that our Members aren't affecting these small caps will I consider reopening Membership rolls.
But right now you can join MicroCap HotSheet as one of our select Members.
This way, you'll have a virtually never-ending stream of potentially highly profitable recommendations arriving in your e-mail box like clockwork.
I can't think of any better way to indulge in the lucrative world of micro caps than through MicroCap HotSheet. And here's the best part.
These special Membership spots will be on a first-come, first-serve period. No exceptions.
With this letter going to my 23,000 readers, as well as over 327,000 investors worldwide, I expect these Member spaces to sell out very quickly, probably within the next few hours.
Membership is probably less than you would imagine it to cost.
My publisher suggested we charge at least $4,500 annually for MicroCap HotSheet.
But I'm so excited about the potential this tiny $1.75 medical device company offers, I didn't want price to be an issue. So here's the deal...
If you're among those MicroCap HotSheet Members who sign up during this limited time, you can enroll today for only $1,750.
That's a ridiculously low price.
But please understand: This offer is only for those who respond during this special limited enrollment period and have met the three required qualifications.
And don't forget, you'll get ongoing access to remarkable profit micro-cap sensations. Force Protection, which soared from 70 cents to $13... and Tix Corp., which bolted from 35 cents to $4.20... and Katanga Mining, which launched from $1.14 to $8.45 are just a few micro-caps that have delivered the goods to their shareholders in recent years.
And best of all, the moment I hear from you, I'll send you the Special Report with all the details on the $1.75 stock NBC couldn't risk revealing that could likely hit $20 in the next two years.
But I'm not naive. I know that $1,750 is still a sizeable financial commitment. And maybe you're not quite sure you're ready to delve into the fast-moving market of penny stock goldmines head on.
So I've got another offer for you, that may help put you at ease...
Try Us for a Quarter and Then Decide!
If you're not ready to commit to MicroCap HotSheet for an entire year, then let me do this for you.
I've arranged so that you can join us as a Member on a quarterly basis for only $439.
You'll sign up for the next three months and receive my Special Report on this $1.75 "modern medical miracle" immediately just as you would if you joined for a year.
Once your quarter is up, we'll renew you automatically for the next quarter. You don't need to pick up the phone, send in a renewal notice or lift one finger.
Your service will continue uninterrupted until you tell us to stop.
It's a safe and easy way to enjoy all the benefits of MicroCap HotSheet but without a bigger commitment of time and money you might not be comfortable with at the moment.
And you still receive all of the details on this emerging quadruple-digit opportunity that I've told you about today. Yours to keep forever -- no questions asked.
I think you'll agree: Not only is this opportunity a bargain... it could also make you very rich. And here's my personal promise to you:
I Give You My Word...
Go ahead now and give MicroCap HotSheet a try. Reserve your space before it sells out. The moment I hear from you, I'll send you the Special Report. Read it. And then grab a few shares of this $1.75 stock.
And do it quickly... because this stock is getting ready to soar.
And listen: If we haven't delivered at least 200% gains by the end of 2007, just say the word. I'll refund every penny of your subscription.
And you know what? If you decide to join us for the next year and for any reason you aren't happy, just let me know in the next 90 days. I'll refund your entire subscription fee. Why wouldn't I? The waiting list is going to be a mile long...
Or choose to join us on our automatic quarterly billing option for only $439/quarter.
Whichever Membership choice you make, I'm absolutely confident you'll be patting yourself on the back in just a few short months when you take a look at the list of winners in your portfolio.
The important thing is for you to get in now, reserve your space, and seize what could be a once-in-a-lifetime opportunity.
Just click the subscribe button below or call us Monday-Friday, 9:00 a.m.-5:00 p.m., at 1-877-465-1416.
Do it now... the next hot penny-stock goldmine is waiting, but not for long.
Sincerely,
A.M. Sosnowski
Editor, MicroCap HotSheet
P.S. Things are heating up faster than expected. Days after announcing one product, the company came out with another. The stock is up over 100% from the beginning of 2007 alone!
And just because NBC didn't reveal the name of the company during its story, doesn't mean savvy investors won't be figuring it out soon enough. With all the news coming out of this company, it's only a matter of time before the news on this technology is blown wide open.
You have to get in while you can still only pay a few dollars for a share of this blockbuster medical device micro-cap stock!
P.P.S. Don't forget: As a Member of MicroCap HotSheet, you'll get a never-ending flow of hot micro-cap resource stocks... delivered to your inbox like clockwork. But we can only offer Membership for a limited time. So please act now to reserve your space.
Information as of April 14, 2007
Signalife Submits Fidelity 200 Cardiac Event Recorder Pre-Market Notification to FDA
Thursday May 3, 9:04 am ET
GREENVILLE, S.C., May 3 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that it has submitted its Fidelity 200 Cardiac Event Recorder 510K pre-market notification to the FDA. Upon clearance the recorder will be sold over-the-counter.
There is no widely accepted over-the-counter product on the market today. Utilizing the Company's proprietary signal processing technology and amplification process, the exceptional signal clarity of this device will allow it to become a new standard in cardiac event recording.
Other significant benefits of the Fidelity 200 include its credit card size and ease of use where a user simply places it on their chest and following three easy steps records and transmits their ECG to the monitoring center. The Fidelity 200 is user friendly to individuals concerned about their current health risks and individuals who have the desire for long term ECG monitoring. Signalife believes that this product will consolidate and create a new market that addresses not only the event monitor market but the wellness market as well, by providing individuals information about their heart health prior to the onset of cardiovascular disease.
It is thought that this recorder will provide patients with an additional possibility to monitor their heart when they are no longer eligible for Medicare-reimbursed event recorders. Through an educational program developed to assist physicians in understanding the benefit of this device to their practice and patients, the Fidelity 200 will be presented as a product that physicians can recommend to their patients.
Users will identify their physician during the enrollment process to the monitoring service. This will allow any irregular ECG results obtained by the monitoring center to be reviewed by the physician who will provide a diagnosis to the patient.
"We are pleased to offer a new product that will provide consumers with the same sophisticated technology used by hospitals and physicians, that allows the patient to make informed decisions regarding their cardiac health when the reimbursement for existing products may not apply," states Pamela Bunes, company CEO.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Signalife Develops Proprietary Software for Objective Evaluation of Electrocardiograph Performance
Wednesday April 18, 9:09 am ET
http://biz.yahoo.com/prnews/070418/nyw077.html?.v=99
GREENVILLE, S.C., April 18 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced development of proprietary software that can provide objective evaluation of electrocardiograph performance, including its Fidelity 100 ECG system.
Presently, the objective evaluation of different ECG recorders is performed by parallel recordings of the device under test and the control device. In the case of differences between the two, it is difficult to determine which device recorded the source signal with higher fidelity. A combination of the Signalife simulator and newly developed proprietary software will allow the objective comparison of different electrocardiograph devices.
Budimir S. Drakulic, Signalife's Chief Technology Officer stated, "We have spent considerable time and effort in the development of a simulator and proprietary measurement software. This technology was used to demonstrate the superiority of our Fidelity 100 recorder against electrocardiograph recorders from leading manufacturers. We intend to report our findings in various upcoming scientific meetings."
Pamela Bunes, Company's CEO concluded, "Since the company's inception, we publicized that our technology improves ECG recordings, especially in ambulatory settings. Our presentation at the ISCE meeting in 2005 focused on an important characteristic of modern electrocardiograph devices that incorporates different filter settings to improve visual appearance of ECG tracings. It seems that the electrocardiology community responded well to our efforts to bring attention to this problem as a recent paper by Dr. Paul Kligfield and Dr. Peter Okin entitled 'Prevalence and Clinical Implications of Improper Filter Settings in routine Electrocardiography' published in the March 1st, 2007 issue of the American Journal of Cardiology indicates that our initiative is gaining support. Signalife commits to provide the best possible solution to clinicians and ultimately patients."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance for heart monitoring and other biomedical devices incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical devices incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
Signalife Completes Phase One of Its Distribution Strategy
Monday April 16, 9:38 am ET
http://biz.yahoo.com/prnews/070416/nym095.html?.v=59
GREENVILLE, S.C., April 16 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News)
Signalife announces it has hired a new distribution organization for its Fidelity 100 product line. The group consists of independent distributor reps for cardiac rhythm management products (ICD's and pacemakers). The initial focus will be the Southern region from North Carolina to Texas, but additional representation is already under consideration in other areas of the country. The initial number of sales representatives will start at 25 and may increase to 50 before year end.
"This is a very exciting development for Signalife as the independent representatives are experienced and understand the significance of our technology and product. They have existing relationships with physicians and hospitals that mirror the desired call points for our company. We are pleased to complete phase one of this distribution channel, and look forward to results created by a professional sales force within the industry," stated Pamela Bunes, CEO of Signalife, Inc.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
A central New York network is very slowly bringing a word-of-mouth marketing awareness through lets say friends of SGN.
Yep its beginning to look good again TechKim my thoughts were it would do a typical retracement back to around 1.30 but that may not happen...but I would not count it out just yet.
If it doesn't break that last low around 1.60 then I would say its taking its next leg up...which I expect would be around 3 bucks.
It just depends on what the company wants and how they go about it...but the good part is that things are looking up and 1.60 looks like support now.
Good luck
Willie Gault Demonstrates Signalife's Fidelity 100 at American College of Cardiology Scientific Session on March 26, 2007
GREENVILLE, S.C., March 26, 2007 /PRNewswire-FirstCall via COMTEX/ -- Signalife, Inc. (Amex: SGN) features Willie Gault demonstrating it's latest technology in booth #2875 at the American College of Cardiology Scientific Sessions Monday, March 26, 2007.
Willie Gault, Chicago Bears Super Bowl Champion, returns to New Orleans, where in 1986 he played to win the Super Bowl 20 Championship. Gault is demonstrating the Signalife heart-monitoring device, invented by Dr. Budimir Drakulic. Dr. Drakulic's patented breakthrough technology provides a unique platform for biomedical signal acquisition, classification and evaluation for the treatment of cardiovascular diseases.
Willie Gault and other world class Hall of Fame athletes, believe this device will save the lives of athletes and others who die of sudden cardiac arrest in this country and around the world. Gault founded the 501 C 3 charity foundation "Athletes For Life" to provide Signalife (www.signalife.com) heart monitors to YMCA, Boys and Girls Clubs, underprivileged high schools and colleges across the country. Willie Gault will access corporate sponsorship and donations to reach his goal of reducing the prevalence of sudden cardiac death in children and adults who have not already been diagnosed with cardiovascular disease.
Gault quotes, "This device is the most important device invented to help prevent sudden heart attacks in people young and old alike. We all have been affected by this problem. On a personal note I have lost six friends over the last two years, so it has become my mission to assist in the fight against cardiovascular disease. I am excited about the possibility of saving lives!"
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.
CONTACT: Kevin Kading, +1-212-918-4606, for Signalife, Inc.
URL: http://www.Signalife.com
http://www.prnewswire.com
www.prnewswire.com
Copyright (C) 2007 PR Newswire. All rights reserved
Signalife, Inc. Unveils Fidelity 300 at ACC - March 24-27
Tuesday March 20, 9:37 am ET
http://biz.yahoo.com/prnews/070320/nytu085.html?.v=91
GREENVILLE, S.C., March 20 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) Signalife, Inc. announced on March 25 through March 27, at the American College of Cardiology 56th Annual Scientific Session in New Orleans, Louisiana, Signalife will unveil its new Fidelity 300 heart monitor. The Fidelity 300 provides superior long-term clinical quality monitoring capabilities from a device housing in a light and portable enclosure.
To demonstrate the efficacy of the Signalife technology, world-class athlete and Super Bowl winner Willie Gault -- from the 1985 Super Bowl Champion Chicago Bears -- will wear the Fidelity 100 and 300 devices while running on a treadmill at world class speeds. The device will garner a clinical quality ECG signal on a wide screen monitor for easy viewing. The demonstration will take place twice daily on Sunday and Monday at the company's booth #2875.
The Fidelity 300, built on the basis of the same award winning technologies as the Fidelity 100 which is currently in use, will be used for long term ECG recordings in clinical studies that are expected to start this summer and shall be announced by the Company soon.
"We are delighted to share the long awaited product line extension with a demonstration of the Fidelity 300. The Research and Development Team have been working hard to unveil the Fidelity 300 at the ACC Meeting and we are exited about this and other new products presently under development. These are very exciting times for the company and for the cardiology community. We expect to make a significant contribution to the diagnosis and treatment of cardiovascular disease," states Pam Bunes, President and Chief Executive Officer.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: Signalife, Inc.
SGN - Huntleigh has a Cardiac Montior on web page! Take a peek!
http://www.huntleigh-technology.com/ watch the picture blink back and forth!
=========================================================
Signalife Announces Negotiations With Huntleigh-Technology, PLC
Tuesday February 27, 11:00 am ET
http://biz.yahoo.com/prnews/070227/nytu129.html?.v=85
=============================================================
Not saying that is a SGN cardiac monitor! But very well could be shortly!
=============================================================
http://www.medilogdarwin.com/resources/medilog_fd5.gif
============================================================
http://www.nesbitevans.com/altproductftp/uk/diagnostics/vitalsigns/index.htm
SGN -- face to face due diligence. Actually I went behind the company to find credibility and authentication of identity.
1) I introduced the Signalife web page to several cardiologist. A few are known OPEN HEART surgeons in this Upstate New York region.
===================================================== =====
2) Cardiologist were familiar with Dr. Zachariah P. Zachariah of Ft. Lauderdale, Florida who recently was appointed as a medical and business consultant to the Company
===================================================== ==
3) All the cardiologist who viewed the breakthrough in the cardiac monitoring were simply impressed. They were impressed with the Technology Breakthrough page. http://www.signalife.com/Pages/What-Card...
=============================================
Zachariah - outstanding consistent articles
http://www.highbeam.com/search.aspx?q=Zachariah&ref_id=ency_botnm
===================================================
Zachariah Family Wellness Pavilion
http://www.holy-cross.com/wellness/index.php?page=homePage
================================================================
To draw a big name like Zachariah into your organization. YOU BEST HAVE THE GOODS!
=============================================================
$400 billion cardiac disease market! SGN will likely take a portion of it. Very possibly, Huntleigh will be the SGN partner.
http://www.huntleigh-technology.com/huntleigh/investors/index.jsp
Huntleigh is a major international company serving the global healthcare market with high quality medical equipment. 2000 employees in 120 countries.
============================================================
SIGNALIFE INC (AMEX:SGN)
http://finance.yahoo.com/q?s=SGN
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
192
|
Created
|
01/08/07
|
Type
|
Free
|
Moderators |
PLEASE READ THE RECENT LAWSUIT NEWS RELEASE.
Junk Faxes to Promote Stock; Signalife Loses Lawsuit
http://www.knobias.com/story.htm?eid=3.1.f275d1b75a8b45267c5519ae04a78b714e97f420528599f5ebdbe706f2dfd505
Peter Strojnik, P.C. Files First Amended Complaint Alleging Signalife, Inc. Engaged in Mass Broadcasting of Junk Faxes to Promote Its Stock; Signalife Loses Strojnik Lawsuit
Wednesday, November 05, 2008 12:30ET
PHOENIX, Nov 05, 2008 (BUSINESS WIRE) -- On October 7, 2008, Peter Strojnik, P.C. filed a first amended complaint in its proposed class action lawsuit against Signalife, Inc. in the United States District Court for the District of Arizona, case number 2:08-cv-1116, alleging the medical supply company engaged in a mass-broadcast of junk faxes to promote its stock.
President and CEO of Peter Strojnik, P.C., Peter Strojnik, opined that Signalife certainly has a motive to pump up the price of their stock. The Complaint alleges "Signalife had a net loss for the six months ending June 20, 2008 in the amount of $8,826,795.00." Mr. Strojnik added, "Signalife admitted in a recent Form 10Q that they had no revenues from product sales during the first half of 2008." Indeed, the Complaint alleges "Signalife has no sales revenues and admits ... that its inability to generate revenues could cause it to go out of business."
Signalife has not gone out of business, but they have been delisted from the American Stock Exchange. In fact, Signalife recently affected a 4500 for 1 reverse stock split and started trading on the OTCBB and Pink Sheets.
Mr. Strojnik explained that the Telephone Consumer Protection Act awards damages at a minimum of $500 for each unsolicited fax. The proposed class action lawsuit against Signalife and others alleges Defendants broadcasted between approximately 12 million to 16 million unsolicited faxes.
In what Mr. Strojnik opined was a defense tactic, Signalife, Inc. filed a Complaint for Declaratory Relief against Peter Strojnik, P.C. in Los Angeles. Signalife sought a decree that it did not violate the TCPA. After several months of argument and deliberations, Orange County Superior Court dismissed the case.
Peter Strojnik, P.C.'s proposed class action lawsuit alleges that "The purpose of the Unsolicited Fax was to manipulate SGN stock or any publicly traded Signalife stock in the securities market." Mr. Strojnik opined, "Signalife cannot be allowed to violate federal law without redress for the regular people who receive these annoying faxes." Paraphrasing the allegations of the Complaint, Mr. Strojnik stated, "In my opinion, Signalife or its insiders hired a third party fax blaster to broadcast millions of faxes promoting its stock." Indeed, Signalife admits in its most recent Form 10Q that they are "in discussions with a number of large third party marketing and distribution partners with the manpower and financial resources to more quickly and aggressively promote [its] products."
Other defendants in the class action lawsuit include Digitalspeed Communications, Inc. and Adam Harris Pasternack.
For more information, please contact Peter Strojnik at ps@strojnik.com or at (602) 524-6602.
SOURCE: Peter Strojnik, P.C.
Peter Strojnik, P.C.
Peter Strojnik, 602-524-6602
ps@strojnik.com
Copyright Business Wire 2008
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |